mercredi 6 mai 2020

Onco Actu du 6 mai 2020


4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



Exeter student leads research concluding that small red blood cells could indicate cancer [University of Exeter]











4.10 DÉP., DIAG. & PRONO. - POUMON



AI Helps Predict Lung Cancer Risk [Johns Hopkins]











4.17 DÉP., DIAG. & PRONO - ECONOMIE



Bayer and NeoGenomics Launch the Test4TRK™ Program to Provide Genomic Cancer Testing at No Cost for People Living with Advanced Thyroid and Colorectal Cancers [Bayer]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



New tumour sampling method significantly improves genetic testing for cancer treatment [Francis Crick Institute]










Germline genomic profiles of children, young adults with solid tumors to inform management and treatment [Medical XPress]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Libtayo® (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma [Sanofi]











5.17 TRAITEMENTS - RADIOTHÉRAPIE



MRI technique could reduce need for radiation in measuring tumor response to chemotherapy [NCI]










5.2 PHARMA



Seattle Genetics' bladder cancer med Padcev blows early expectations out of the water [Fierce Pharma]











5.2.6 PHARMA - BIOTECH



TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia [TG Therapeutics]











TG Therapeutics' leukemia combo clears phase 3, aims for 2020 filing [Fierce Biotech]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



FDA Approves Niraparib for First-Line Maintenance Treatment of Advanced Ovarian Cancer [ESMO]











6.15 LUTTE CONTRE LES CANCERS - COVID-19



A cancer patient reconsiders her end-of-life wishes, as Covid-19 brings mortality into sharper focus [STAT]











COVID-19 vs. community oncology: Flatiron’s data provides first damage assessment [The Cancer Letter]